Myriad Reports Positive Results for Alzheimer's Drug
Posted on: Monday, 5 March 2007, 15:00 CST
Myriad Genetics has said that its Alzheimer's drug Flurizan may have disease modifying capabilities.
In the phase II trial, many patients with Alzheimer's disease got no worse over two full years, and in some cases, patients treated with Flurizan appear to have improved, according to the US biopharmaceutical company.
At 24 months, study participants in the phase II trial with mild Alzheimer's disease taking 800 mg twice daily Flurizan experienced a 67% improvement in their level of cognitive decline compared with placebo, as measured by the Mini Mental State Exam (MMSE) score. Additionally, 42% of patients on 800 mg twice daily Flurizan experienced improvement or zero decline, compared with 14% of patients taking placebo.
"The 24 month phase II responder analysis provides further evidence of efficacy against mild Alzheimer's disease that is consistent with our understanding of Flurizan's mechanism of action as a SALA," said Adrian Hobden, president of Myriad Pharmaceuticals.
"The results support our belief that Flurizan is modifying the course of the underlying disease process."
Source: Datamonitor
Related Articles
- Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
- The Lancet Neurology Publishes Clinical Results of PBT2 in Alzheimer's Disease Patients
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
- Abbott's Humira Found Effective in Crohn's Disease Patients With Fistulas
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- $4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
- ZIOPHARM Treats First Patient in Phase II ZIO-101 Liver Cancer Trial
- Enzo Therapeutics Treats First Patient in Phase I/II Study of Antisense Gene Therapy for HIV-1 Infections
- MedImmune Begins Dosing of Lupus Patients in Phase 1 Clinical Trial
 |
 |
User Comments (0)
RSS Feeds